Evidence strength for the context described on this page.
PEPTIDE ATLAS / METABOLIC & FAT LOSS / SEMAGLUTIDE
FDA-approvedHigh for approved indication
Semaglutide
ALSO KNOWN ASWegovy · Ozempic · Rybelsus
A GLP-1 receptor agonist with strong outcome data for defined metabolic indications.
01CATEGORYMetabolic & fat loss
02REGULATORY STATUSFDA-approved
03COMMON ROUTESubcutaneous injection; an oral tablet exists for selected indications
04DOSE BASISFDA-approved label
HOW TO USE THIS PAGE
Read the profile in the order that protects the decision.
- 01Verify what it is
Confirm the exact molecule, route, regulatory lane and actual human evidence.
- 02Read limits before dose
Unsupported claims, contraindications and uncertainty come before any protocol.
- 03Build the monitoring plan
Define the target, baseline checks, reassessment point and stop rules with a qualified clinician.
RESEARCH PASSPORT
The five facts to know first.
REVIEWED
JULY 2026
Status is product-, formulation- and indication-specific.
Trial, label or reported-practice basis is always named.
Official labels, regulators, trials and indexed literature where available.
Peptide hormones, growth factors and related substances may be prohibited.
Check Global DRO ↗OVERVIEW
What Semaglutide is.
A long-acting peptide analog of glucagon-like peptide-1. Different branded products have different indications, formulations and dose schedules; they are not interchangeable simply because the active ingredient is related.
HOW IT IS THOUGHT TO WORK
Activates GLP-1 receptors, increasing glucose-dependent insulin signaling, reducing glucagon when glucose is elevated, slowing gastric emptying and changing appetite signaling.
EFFECTS & EVIDENCE
What the evidence supports—and what it does not.
- Substantial average weight reduction in eligible adults when paired with long-term lifestyle care
- Improved glycemic control in type 2 diabetes
- Cardiovascular risk reduction for specific labeled populations
- A universal weight-loss drug for anyone wanting to be leaner
- A substitute for resistance training, adequate protein or clinical follow-up
- That compounded or salt-form products are equivalent to FDA-approved brands
Evidence grade: High for approved indication. For an approved drug, “high” refers only to its labeled indication—not every off-label or wellness claim.
DOSAGE CONTEXT
Best available dosing range.
FDA-APPROVED LABELApproved obesity injection labeling starts at 0.25 mg once weekly and escalates in 4-week steps toward a maintenance dose commonly 1.7 or 2.4 mg weekly. Other semaglutide products use different schedules. This is label context, not an individualized prescription.
- Route
- Subcutaneous injection; an oral tablet exists for selected indications
- Duration
- Chronic treatment when effective and tolerated; stopping commonly leads to regain
- Men & women
- No routine male/female dose split. Pregnancy, planned pregnancy and breastfeeding require specific prescriber guidance.
Clinician verification required. Always double-check the exact molecule or salt, concentration, route, volume, schedule, indication, patient-specific contraindications, interactions and applicable law with the prescribing clinician and dispensing pharmacy. A disclaimer does not make an unapproved product FDA-approved, and a reported-use range is not a prescription.
MONITORING
What should be tracked.
- Weight trajectory, waist and functional goals
- Glucose and diabetes-medication adjustment when relevant
- Hydration, GI tolerance and gallbladder symptoms
- Lean-mass preservation through nutrition and resistance training
SAFETY
Risks, red flags and reasons to avoid it.
- Nausea, vomiting, diarrhea, constipation and abdominal pain
- Gallbladder disease, pancreatitis warning and dehydration-related kidney injury
- Hypoglycemia when combined with insulin or insulin secretagogues
- Boxed thyroid C-cell tumor warning; contraindicated with personal/family MTC or MEN2
- Pregnancy
- Personal or family history of medullary thyroid carcinoma or MEN2
- Using multiple GLP-1 drugs together
- Unverified products sold without a lawful prescription
Stop and seek careGet urgent medical help for trouble breathing, facial or throat swelling, chest pain, fainting, severe persistent abdominal pain, neurologic changes, severe hypoglycemia, uncontrolled vomiting or a prolonged painful erection.
CLINICIAN VISIT CHECKLIST
Six questions worth bringing with you.
Molecule or analog, salt, concentration, route, manufacturer or compounder, lot and beyond-use date.
Name the diagnosis or target, how it will be measured and the realistic time to reassess.
Ask how it compares with FDA-approved, lower-risk or better-studied alternatives.
Label, human trial, specialty guideline or clinic convention—and whether that route and formulation match.
Baseline checks, follow-up measures, interactions, pregnancy considerations and symptoms that mean stop.
Pharmacy license, prescription, identity/potency testing, sterility controls and who handles a product complaint.
Do not improvise reconstitution or convert “units” without the exact concentration. Mixing, storage and beyond-use instructions are product-specific; confirm them with the dispensing pharmacy.
PRIMARY SOURCES
Read the record yourself.
We prioritize official prescribing information, FDA regulatory material, registered trials and indexed biomedical literature. A source supports the specific statement beside it—not every claim made about the molecule.
PRODUCTS & TREATMENT ACCESS
Use a verified prescription pathway.
Prescription-only FDA-approved products. FDA states compounded drugs are not FDA-approved and has warned about dosing errors, salt forms and misleading equivalence claims.
The molecule has high-quality evidence; product provenance still matters. A vial marketed as semaglutide is not automatically equivalent to a branded, approved product.
Compare qualified specialists
Coming soon: indication-matched clinicians, transparent pricing, required monitoring and verified prescription sourcing.
Join the treatment shortlist →NEXT STEP